cagrisema semaglutide cagrilintide phase 3 results 2024 2025 Cagrilintide–semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, study ADA 2025: CagriSema Demonstrates Significant

Evidence is extrapolated from wound healing studies and in vitro chondrocyte research

At Duke Healths Hillsborough Primary Care Center in North Carolina, providers have been prescribing compounded versions of the drugs while the brand-name versions are in shortage

FDA has documented adverse events including overdoses from dosing errors - get explicit measurement guidance from provider before first injection FTC precedent: FTC December 2025 NextMed enforcement action involved undisclosed GLP-1 subscription costs

Insurance plan copays may have affected cost considerations, but the individuals in this analysis were not paying out-of-pocket for their treatment